Fox Chase Cancer Center News

June 2, 2023

Fox Chase’s Dr. Elizabeth Plimack Appointed Treasurer of American Society of Clinical Oncology

PHILADELPHIA (June 2, 2023)—Elizabeth Plimack, MD, MS, Deputy Director and professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, has been appointed Treasurer of the American Society of Clinical Oncology (ASCO).

VIEW STORY

June 2, 2023

Fox Chase Cancer Center and Temple Health Present Research at the 2023 ASCO Annual Meeting

PHILADELPHIA (June 2, 2023)—Fox Chase Cancer Center and Temple Health researchers will participate in the presentation and discussion of 10 research projects at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held June 2-6 in Chicago. An asterisk (*) indicates that the author is the main presenter.

VIEW STORY

June 1, 2023

Fox Chase Cancer Center Researchers Show Alternate Response Criteria May Allow Early Outcome Prediction in Pancreatic Neuroendocrine Tumors

PHILADELPHIA (June 1, 2023) — Researchers at Fox Chase Cancer Center have utilized banked computed tomography (CT) to evaluate alternate response criteria for early prediction of outcomes in rare pancreatic neuroendocrine tumors (NETs).

VIEW STORY

May 31, 2023

Fox Chase Cancer Center Study Challenges Assumptions About Cystic Renal Masses

PHILADELPHIA (May 31, 2023)—Cystic renal masses are a common type of kidney lesion that are generally considered to be low-risk and unlikely to spread beyond the kidney. Now a new study from Fox Chase Cancer Center that was featured on the cover of the Journal of Urology, published by Wolters Kluwer sheds more light on these lesions.

VIEW STORY

May 30, 2023

Fox Chase Cancer Center Accredited by Smoking Treatment Accreditation & Recognition Program

PHILADELPHIA (May 30, 2023)—Fox Chase Cancer Center has been accredited by the Smoking Treatment Accreditation & Recognition (STAR) program, a tobacco treatment initiative funded through a grant from the Pennsylvania Department of Health.

VIEW STORY

May 30, 2023

Temple Health and Fox Chase Cancer Center Researchers Reveal the Importance of Three Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer

PHILADELPHIA (May 30, 2023)—Patients with muscle-invasive bladder cancer who receive fewer than three cycles of chemotherapy prior to bladder removal surgery face higher risk of recurrence and worse survival outcomes. That’s according to research from Temple Health and Fox Chase Cancer Center that will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

VIEW STORY

May 26, 2023

Case Study Shows That Drug Sensitivity Testing Could Help Personalize Chronic Lymphocytic Leukemia Treatment Selection

PHILADELPHIA (May 26, 2023) — Management of chronic lymphocytic leukemia (CLL) is a rapidly evolving field, so choosing between the growing number of effective, available therapies can be challenging for both physicians and patients.

VIEW STORY